119 filings
Page 3 of 6
8-K
6dz2qra0luiyzoscz
1 Jul 22
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
4:34pm
8-K
y125l3i
7 Jun 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
ap5zqpnv4kp1mv5vrhsw
20 May 22
Regulation FD Disclosure
4:12pm
8-K
vtu 070fnkcms6et2xz
12 May 22
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
r9c f6qiulc
17 Mar 22
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
8:23am
8-K
ywyvo8wt c6sn2wmod3m
3 Mar 22
Entry into a Material Definitive Agreement
4:18pm
8-K
os05s
9 Feb 22
Entry into a Material Definitive Agreement
4:10pm
8-K/A
85h 8chgy622
26 Jan 22
Results of Operations and Financial Condition
7:56am
8-K
gk684jrvbqe
25 Jan 22
Results of Operations and Financial Condition
5:13pm
8-K
fqpv1mu algbjvbfpo20
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
8-K
5uf i65yd
14 Jan 22
Termination of a Material Definitive Agreement
4:10pm
8-K
pissgec v0lbf7tmxt
13 Dec 21
Regulation FD Disclosure
5:24pm
8-K
66r5oo4dg1 hwtbc0tx
15 Nov 21
Regulation FD Disclosure
4:11pm
8-K
sdpdo6q 8s
12 Nov 21
Departure of Directors or Certain Officers
4:05pm
8-K
knjctrxaarcy603pm
5 Nov 21
Entry into a Material Definitive Agreement
5:27pm
8-K
7g2ss
4 Nov 21
Results of Operations and Financial Condition
9:01am
8-K
gys6ejy4
19 Oct 21
Departure of Directors or Certain Officers
4:56pm
8-K
se1hkavfzqffe qz
10 Sep 21
Departure of Directors or Certain Officers
4:04pm
8-K
nxpkxnofbt xh
6 Aug 21
Regulation FD Disclosure
4:05pm
8-K
i4uc46i8t
3 Aug 21
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter
8:12am